**TO THE EDITOR**

In recent years, a regulatory role has emerged for the glycan-binding protein galectin-9 (Gal-9) in normal physiology and pathology (reviewed by [@bib8]). In melanoma and other malignancies, the available data suggest that Gal-9 has a tumor-suppressor function, with loss of Gal-9 being closely associated with metastatic progression ([@bib5]; [@bib4]; [@bib9]; [@bib6]). In particular, melanocytic nevi and primary melanoma lesions highly express Gal-9, whereas metastatic melanoma lesions have no or minimal expression of Gal-9 ([@bib5]). Furthermore, ectopic expression of Gal-9 abrogates the formation of metastases by Gal-9-deficient B16F10 murine melanoma cells ([@bib7]). Similarly, treatment of Gal-9-deficient B16F10 cells with a recombinant form of Gal-9, designated Gal-9(0), strongly reduced metastasis formation ([@bib7]).

This anti-metastatic activity of Gal-9(0) on B16F10 has been attributed mainly to inhibition of melanoma cell adhesion to endothelial cells and/or extracellular matrix components, such as collagen type I (collagen-I; [@bib7]). The data presented in the current letter suggest that within the 1-h time frame of adhesion-type assays, treatment with Gal-9(0) triggers early apoptotic cellular changes. In line with earlier findings, Gal-9(0) inhibits the adhesion of B16F10 and 7 human melanoma cell lines to collagen-I ([Figure 1a](#fig1){ref-type="fig"}). However, the morphology of Gal-9(0)-treated cells that had adhered to collagen-I-coated wells resembled that of dying cells ([Figure 1b](#fig1){ref-type="fig"}; illustrated for B16F10). Subsequent analysis of this melanoma cell line panel, as well as primary patient--derived malignant melanoma cells for the early apoptotic marker phosphatidyl serine (PS), revealed that treatment with Gal-9(0) induced ∼90% cell death within the time frame used in the adhesion assay ([Figure 1c](#fig1){ref-type="fig"}). Early apoptotic PS exposure was followed by apoptotic cell death within 24 h of treatment, as evidenced by loss of viability ([Supplementary Figure S1a](#sup1){ref-type="supplementary-material"} online), the presence of late apoptotic Annexin-V/PI double-positive cells ([Supplementary Figure S1b and c](#sup1){ref-type="supplementary-material"} online), and an increase in DNA fragmentation ([Supplementary Figure S1d](#sup1){ref-type="supplementary-material"} online). In primary human melanocytes, Gal-9(0) also triggered PS exposure, albeit to a lesser extent ([Figure 1c](#fig1){ref-type="fig"}; ∼55%). More importantly, the viability of these normal cells was not negatively affected after 24 h ([Supplementary Figure S1a](#sup1){ref-type="supplementary-material"} online). Thus, Gal-9(0) induces rapid apoptotic cell death in melanoma cells, but not in normal human melanocytes. PS exposure induced by Gal-9(0) was fully dependent on the glycan-binding specificity of Gal-9(0), as it was selectively blocked by the competitive Gal-9 inhibitor alpha-lactose but not by the irrelevant carbohydrate sucrose ([Figure 1d](#fig1){ref-type="fig"}). Sensitivity to Gal-9(0) did not or only weakly correlated with expression of endogenous Gal-9 ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"} online; *r*^2^=0.250). Time-course analysis in five of the human melanoma cell lines demonstrated that treatment with Gal-9(0) induced PS exposure in \>60% of melanoma cells within 5 minutes of treatment ([Figure 1e](#fig1){ref-type="fig"}). Furthermore, the extent of PS exposure closely correlated with the inhibitory effect of Gal-9(0) on collagen I binding ([Figure 1f](#fig1){ref-type="fig"}, MM-RU; *r*^2^=0.693). Together, these data suggest that the biological effect of Gal-9(0) in adhesion assays is mediated, at least partly, through the induction of cell death. It is noteworthy that pan-caspase inhibition failed to block the anti-adhesive and apoptotic activity of Gal-9(0; [Supplementary Figure S1e and f](#sup1){ref-type="supplementary-material"} online). Thus, Gal-9(0)-mediated melanoma apoptosis does not require caspase activation, which is in line with e.g. reports on gal-1-mediated cell death of T cells ([@bib3]).

Adhesion assays are typically performed in serum-free conditions, whereas in normal physiological situations the presence of serum and/or plasma components may affect the biological activity of Gal-9. Indeed, it is well established that Gal-9 can interact with serum components ([@bib2]). Therefore, the biological activity of Gal-9(0) was next evaluated in the presence of 10% fetal calf serum (FCS), the standard serum additive in cell death assays. The inclusion of 10% FCS in these apoptosis experiments completely abrogated the morphological changes in melanoma cells, with induction of PS exposure by Gal-9(0) being abrogated in six of the seven cell lines tested ([Figure 2a](#fig2){ref-type="fig"}). Similarly, PS exposure by Gal-9(0) was also strongly inhibited in the primary melanoma cells ([Figure 2a](#fig2){ref-type="fig"}). Indeed, FCS dose dependently inhibited PS exposure induced by Gal-9(0) (illustrated for cell line A2058 in [Figure 2b](#fig2){ref-type="fig"}) and blocked the binding of Gal-9(0) to A2058 cells ([Figure 2c](#fig2){ref-type="fig"}). When using dialysed FCS or heat-inactivated FCS, the activity of Gal-9(0) was still inhibited ([Figure 2d](#fig2){ref-type="fig"}). Thus, the inhibitory component present in FCS is not heat labile (i.e., complement factors) and is \>10 kDa in size. Notably, FCS did not inhibit Gal-9(0) activity toward SK-MEL-28 cells ([Figure 2a](#fig2){ref-type="fig"}), which suggests that the inhibitory effect of FCS is not merely due to binding of a serum component to Gal-9(0). Possibly, a serum component may shield the receptor(s) of Gal-9 on most melanoma cells. On Sk-MEL-28 cells, Gal-9(0) may interact with an alternative receptor not subject to binding/inhibition by FCS.

Although FCS is the standard additive in *in vitro* cell death assays, a better approximation of physiological settings is the addition of human plasma. Importantly, 10% human pooled plasma did not abrogate Gal-9(0)-induced PS exposure in A2058 cells, with only a slight reduction in PS exposure compared with serum-free conditions ([Figure 2d](#fig2){ref-type="fig"}). Similar results were obtained in six melanoma cell lines and in primary patient--derived melanoma cells ([Figure 2e](#fig2){ref-type="fig"}).

These experiments suggest that an important biological effect of Gal-9(0) on human melanoma cells is the induction of apoptosis. This biological effect of Gal-9(0) is masked by as yet unidentified components present in FCS, but is unmasked in serum-free conditions or when human plasma is used. Indeed, in standard FCS-containing culture conditions, apoptotic cell death of the melanoma cell line MM-RU was only detected after 72 h of treatment with Gal-9 ([@bib5]). The use of FCS may similarly mask the biological activity of other gal family members. In this respect, gal-2, -3, -4, and -8 interact with various serum components ([@bib2]). Notably, plasma levels of several of the gal family members are increased in malignancy ([@bib1]). The use of human pooled serum/plasma instead of FCS for *in vitro* biological assays with members of the Gal family therefore appears prudent.

In conclusion, recombinant Gal-9 has a hitherto unrecognized cytotoxic effect toward human melanoma cells, which further highlights its potential therapeutic applicability for the treatment of human metastatic melanoma.
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![**Galectin-9 (Gal-9(0)) rapidly induces apoptosis in serum-free conditions.** (**a**). Adhesion of B16F10 and a panel of human melanoma cell lines to collagen-I-coated wells is inhibited by recombinant Gal-9. In brief, 3 × 10^4^ melanoma cells were added to collagen-I-coated plates and incubated for 1 h at 37 °C in the presence or absence of 100 n[M]{.smallcaps} Gal-9(0). Subsequently, wells were washed twice with phosphate-buffered saline, and the number of adhered cells was counted in three wells per condition. Experiments were performed in triplicates. (**b**) Light microscopic pictures of B16F10 cells adhered to collagen-I-coated wells in untreated conditions and upon treatment with 100 n[M]{.smallcaps} Gal-9(0). Bar=100 μm. (**c**) Cells were treated for 1 h with 100 n[M]{.smallcaps} Gal-9(0) and subsequently analyzed for the early apoptotic event of phosphatidyl serine (PS) exposure using flow cytometric Annexin-V-FITC staining. The following cells were analyzed: B16F10, A2058, Sk-MEL-28, MM-RU, MM-WK, MM-AN, MM-EP, A375M, primary (prim.) patient--derived melanoma cells (*n*=1), and primary human melanocytes (*n*=1). (**d**) B16F10, Sk-MEL-28, A2058, and MM-RU were treated with Gal-9(0) with or without alpha-lactose or sucrose. (**e**) Sk-MEL-28, A2058, A375M, MM-AN, and MM-RU were treated with 100 n[M]{.smallcaps} Gal-9(0) for 5, 10, 15, and 20 minutes. Graph represents the average PS exposure detected in all five cell lines from three separate experiments. (**f**) MM-RU cells were treated with various Gal-9(0) concentrations (ranging from 5 to 200 n[M]{.smallcaps}), after which cells were simultaneously assessed for collagen-I adhesion and PS exposure. Statistical analysis was performed by linear regression, yielding an *r*^2^ of 0.6497. In all cell death assays, cell death was assessed by flow cytometry using Annexin-V-FITC, which measures the early apoptotic exposure of PS on the outer leaflet of the cell membrane.](jid2012133f1){#fig1}

![**Cell death induction by galectin-9 (Gal-9(0)) is blocked by fetal calf serum (FCS) but not by human pooled plasma.** (**a**) A panel of melanoma cells and primary patient--derived melanoma cells (*n*=1) were treated for 1 h with Gal-9(0) in standard cell death conditions (with 10% FCS). (**b**) A2058 cells were treated with 100 n[M]{.smallcaps} Gal-9(0) in the presence of increasing concentrations of FCS and analyzed for the percentage of cells with phosphatidyl serine (PS) exposure. (**c**) A2058 cells were incubated on ice with 100 n[M]{.smallcaps} biotinylated Gal-9(0) in the presence of increasing concentrations of FCS. Cell surface binding of Gal-9(0)-biotin was evaluated using Streptavidin-Alexa488 by flow cytometry. (**d**) A2058 cells were treated with 100 n[M]{.smallcaps} Gal-9(0) in serum-free (SF) conditions or in the presence of 10% FCS, 10% dialyzed FCS (dFCS), heat-inactivated FCS (hiFCS), or human pooled plasma (HPP). (**e**) A panel of melanoma cell lines and primary patient--derived melanoma cells (*n*=1) were treated with 100 n[M]{.smallcaps} Gal-9(0) in SF conditions or in the presence of 10% HPP. In all assays, cell death was assessed by flow cytometry using Annexin-V (AnneV)-FITC. All experiments were performed in triplicates.](jid2012133f2){#fig2}

[^1]: These authors contributed equally to this work.
